Tuesday November 24 2009 | Biotechnology feed | All feeds
|
|
|
News Articles on Decision ResourcesBroad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In EuropeMALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that the leading dri Sales of Therapies to Treat Diabetic Retinopathy, Diabetic Neuropathy and Diabetic Nephropathy Will Increase by More Than 70 Percent Through 2018WALTHAM, Mass., Nov. 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceuti Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing From $360 Million in 2008 to $450 Million in 2018WALTHAM, Mass., Nov. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018WALTHAM, Mass., Nov. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018WALTHAM, Mass., Nov. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical Neuropathic Pain Drug Market Will Increase From $6 Billion in 2008 to $9.7 Billion in 2018WALTHAM, Mass., Nov. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical Stelara is Expected to Substantially Alter Patient Flow to TNF-Alpha Inhibitors Prescribed for Psoriasis Over the Next Two Years
WALTHAM, Mass., Nov. 11 /PRNewswire/ -- Decision Resources, one of the world& Decision Resources, Inc. Named to Outsell's '10 To Watch' ListWALTHAM, Mass., Nov. 9 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory fir Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018WALTHAM, Mass., Nov. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical a Widespread Generic Erosion of Atypical Antipsychotics Will Cause the Bipolar Disorder Drug Market to Decline By More Than $1 Billion Through 2018WALTHAM, Mass., Nov. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical a Driven by the Launch of Targeted Agents, the Gastric Cancer Drug Market Will More Than Double to Nearly $1.5 Billion in 2018
WALTHAM, Mass., Nov. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and Biosimilars of TNF-alpha Inhibitors Stand to Erode Over $9 Billion in Brand Sales in the U.S. and Europe by 2018
WALTHAM, Mass., Nov. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roche's Actemra for Rheumatoid ArthritisWALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmac TNF-alpha Inhibitors, Most Notably Humira and Remicade, Will Continue to Dominate the Crohn's Disease Drug MarketWALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmac Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug MarketWALTHAM, Mass., Oct. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical TNF-Alpha Inhibitors Will Continue to Dominate First- and Second-Line Biologic Therapy for the Treatment of Rheumatoid Arthritis Through 2011WALTHAM, Mass., Oct. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms foc Majority of Surveyed Physicians Prescribe Cymbalta and Lyrica for Treatment of Fibromyalgia But Neither Agent Has the Majority of Its Uses in First LineWALTHAM, Mass., Oct. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory f Merck's Januvia Gains Ground in Second-Line Patient Share at the Expense of Takeda's Actos
WALTHAM, Mass., Oct. 13 /PRNewswire/ -- Decision Resources, o India's Rheumatoid Arthritis Drug Market Will More Than Double by 2013WALTHAM, Mass., Oct. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on Patient-Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of LifeWALTHAM, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing o Sales of Remicade, Humira and Simponi Will Drive the TNF-Alpha Inhibitor Drug Class to Nearly Triple by 2018 for the Treatment of Ulcerative ColitisWALTHAM, Mass., Sept. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharma Although Most Surveyed Oncologists Prescribe it for Many Cancer Types, Avastin's High Cost Remains a Barrier to Treatment for Some PatientsWALTHAM, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharma China's Breast Cancer Drug Market Will Grow From $165 Million in 2008 to $298 Million In 2013WALTHAM, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing o Fingertip Formulary Accounts(R) Now Offers Access to Comprehensive Real-Time Account Information and Integrated Formulary Data, in a State-of-the Art Web-Based PlatformGLEN ROCK, N.J., July 28 /PRNewswire/ -- Fingertip Formulary((R)) announces the launch of the latest version of Fingertip Formulary Accounts((R For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS TrialsWALTHAM, Mass., July 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical European Prices of 170 Best-Selling Drugs Averaged 40 Percent Less Than U.S. Prices in 2008
WALTHAM, Mass., July 7 /PRNewswire/ -- Decision Resources, one of the world's lead Jeff Stewart Joins Decision Resources, Inc. as Chief Information OfficerFormer IntrinsiQ Executive Will be Responsible for Company's Technology Strategy Aimed at Embedding Decision Resources, Inc. Solutions int Emerging Agents from Pfizer, AstraZeneca, GlaxoSmithKline, Bayer/Onyx and Boehringer Ingelheim, and Increased Use of Existing Agents from Eli L Seventy-Seven Percent of Surveyed Physicians Will Increase Their Use of Carbapenems In the Next Five Years, According to a New Report from AMR Emerging Combination Products from GlaxoSmithKline/Theravance, Boehringer Ingelheim and Novartis Will Drive Growth, According Although Risperidone Is Now Available In Generics, There Is No Clear Evidence of Expanded Uptake in Early Lines of Therapy, According to a New Roche and Schering-Plough Will Continue to be Prominent Players in the Market, According to a New Report from Decision Resources http://www.bioportfolio.com/news/Hepatitis_C_Virus_Market_Will_Expand_Dramatically.html - Monday June 22 2009 Sales of Acetylcholinesterase Inhibitors, Which Currently Dominate the Market, Will Decline by Uptake of Novel Agents from Novexel, Johnson & Johnson and Wyeth Will Drive Growth, According to a New Report from Decisi Overall Market Will Increase by a Modest Principal Factor Driving the Market Decline Will be Singulair's Loss of Brand Exclusivity, According to a New Report from Decision Resourc Only 41 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Re Denosumab and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources A Drug's Activity Against Anaerobes is the Leading Attribute in Antibiotic Selection, According to a New Report from AMR and Decision Reso Emerging Novel Oral Therapies Will Garner 29 Percent of the Total Market in 2018, According to a New Report from Decision Resources Commercial Potential of Market is Reflected in Burgeoning Pipeline of More than 400 Drugs in Development, According to a New Report from Decisi By 2018, Gilead's Quad Will Become the Highest-Selling Antiretroviral in the World's Major Markets, According to a Actemra/RoActemra Will Emerge as the Preferred Biological Drug for TNF-Refractory Patients, According to a New Report from Decision Resourceshttp://www.bioportfolio.com/news/For_the_Treatment_of_Rheumatoid_Arthritis%2C_Market.html - Monday May 18 2009 Western Branded Drug Sales Will Command 54 percent of the Market by 2013, According to a New Report from Decision Resources |
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
